← Back to Search

Antiretroviral Agent

1 for HIV Suppression

N/A
Waitlist Available
Led By Steven G. Deeks, MD
Research Sponsored by National Institute of Allergy and Infectious Diseases (NIAID)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions
No Placebo-Only Group

Summary

Drug resistance may develop in HIV infected patients who take anti-HIV drugs, but most patients do well if they continue taking them. The purpose of this study is to test the effectiveness of a short, intensified course of anti-HIV drugs for controlling HIV infection in adults who have virus resistant to multiple drugs.

Eligible Conditions
  • HIV Suppression
  • Human Immunodeficiency Virus Infection

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Side effects data

From 2007 Phase 4 trial • 142 Patients • NCT00326963
1%
Pneumonia primary atypical
1%
Sinusitis
1%
Cellulitis
1%
Pneumonia
1%
Sepsis
1%
Pneumocystis jiroveci Pneumonia
1%
Renal failure
1%
Asthma
1%
Dyspnoea
1%
Anaemia
1%
Upper Gastrointestinal haemorrhage
1%
Neutrophil count decreased
1%
Metabolic acidosis
1%
Myopathy steroid
1%
Erythema nodosum
100%
80%
60%
40%
20%
0%
Study treatment Arm
Enfuvirtide+PI+ARV's

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: 1Experimental Treatment1 Intervention
Participants will receive enfuvirtide for 6 months

Find a Location

Who is running the clinical trial?

National Institute of Allergy and Infectious Diseases (NIAID)Lead Sponsor
3,320 Previous Clinical Trials
5,364,625 Total Patients Enrolled
Steven G. Deeks, MDPrincipal InvestigatorDepartment of Medicine, University of California - San Francisco
1 Previous Clinical Trials
50 Total Patients Enrolled
~1 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top